20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Replimune Group Inc (REPL) operates in the BIOTECHNOLOGY industry and is headquartered in Woburn, United States with about 465 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2026-03-31, REPL reported $0M in revenue and ($314M) in net income.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | — | ($4M) | ($3M) | ($2M) | ($5M) | ($4M) | ($2M) | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($298M) | ($320M) | ($262M) | ($235M) | ($177M) | ($121M) | ($83M) | ($56M) | ($31M) | ($19M) | ($10M) |
| Operating Margin % | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | ($297M) | ($314M) | ($247M) | ($216M) | ($174M) | ($118M) | ($81M) | ($53M) | ($31M) | ($20M) | ($8M) |
| Net Margin % | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | ($291M) | ($302M) | ($254M) | ($228M) | ($172M) | ($114M) | ($76M) | ($53M) | ($31M) | ($17M) | ($8M) |
| Earnings Per Share (EPS) | $-3.18 | $-3.38 | $-3.07 | $-3.24 | $-2.99 | $-2.26 | $-1.75 | $-1.54 | $-1.33 | $-0.64 | $-0.25 |
| Shares Outstanding (M) | 97M | 93M | 81M | 67M | 58M | 52M | 46M | 34M | 23M | 31M | 31M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $1M | $0M | $0M |
| Gross Profit | — | — | ($2M) | ($2M) | ($2M) | ($1M) | ($1M) | ($1M) |
| Gross Margin % | — | — | — | — | — | -57.6% | — | — |
| Operating Income (EBIT) | ($68M) | ($73M) | ($72M) | ($84M) | ($90M) | ($80M) | ($66M) | ($59M) |
| Operating Margin % | — | — | — | — | — | -5426.6% | — | — |
| Net Income | ($70M) | ($73M) | ($71M) | ($83M) | ($87M) | ($74M) | ($66M) | ($53M) |
| Net Margin % | — | — | — | — | — | -5036.0% | — | — |
| EBITDA | ($66M) | ($75M) | ($68M) | ($82M) | ($89M) | ($72M) | ($65M) | ($58M) |
| Earnings Per Share (EPS) | $-0.72 | $-0.79 | $-0.77 | $-0.90 | $-0.95 | $-0.92 | $-0.79 | $-0.68 |
| Shares Outstanding (M) | 97M | 93M | 92M | 92M | 92M | 81M | 83M | 79M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($279M) | ($280M) | ($192M) | ($185M) | ($128M) | ($82M) | ($61M) | ($61M) | ($25M) | ($16M) | ($7M) |
| Capital Expenditures (CapEx) | $1M | $4M | $7M | $6M | $2M | $2M | $2M | $7M | $3M | $0M | $0M |
| Free Cash Flow (FCF) | ($281M) | ($285M) | ($199M) | ($191M) | ($130M) | ($85M) | ($64M) | ($67M) | ($28M) | ($16M) | ($7M) |
| FCF Margin % | — | — | — | — | — | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — | — | $92M | $28M | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($76M) | ($56M) | ($66M) | ($81M) | ($77M) | ($54M) | ($51M) | ($39M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $1M | $3M | $1M | $2M | $2M |
| Free Cash Flow (FCF) | ($76M) | ($56M) | ($66M) | ($83M) | ($80M) | ($55M) | ($53M) | ($41M) |
| FCF Margin % | — | — | — | — | — | -3727.2% | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $252M | $332M | $551M | $488M | $647M | $461M | $543M | $234M | $154M | $65M | $23M |
| Cash & Cash Equivalents | $185M | $209M | $111M | $74M | $147M | $106M | $183M | $60M | $26M | $18M | $21M |
| Total Liabilities | $147M | $166M | $135M | $113M | $91M | $50M | $44M | $50M | $16M | $93M | $34M |
| Total Debt (Short + Long-Term) | $88M | $87M | $50M | $49M | $32M | $4M | $3M | $13M | $7M | $0M | $0M |
| Total Shareholders' Equity | $106M | $166M | $416M | $375M | $555M | $411M | $499M | $184M | $138M | ($28M) | ($12M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive REPL viewer.
About TickerBase · Data methodology & sources · Privacy · Terms